Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DVA 
DaVita HealthCare Partners Inc (DVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $153.5
1 Year Target Price $153.5
| 1 | Strong Buy |
| 0 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.59% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.84B USD | Price to earnings Ratio 13.4 | 1Y Target Price 153.5 |
Price to earnings Ratio 13.4 | 1Y Target Price 153.5 | ||
Volume (30-day avg) 10 | Beta 1.09 | 52 Weeks Range 126.07 - 179.60 | Updated Date 08/29/2025 |
52 Weeks Range 126.07 - 179.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 2.78 | Actual 2.95 |
Profitability
Profit Margin 6.35% | Operating Margin (TTM) 15.7% |
Management Effectiveness
Return on Assets (TTM) 7.15% | Return on Equity (TTM) 57.94% |
Valuation
Trailing PE 13.4 | Forward PE 12.48 | Enterprise Value 21802088000 | Price to Sales(TTM) 0.75 |
Enterprise Value 21802088000 | Price to Sales(TTM) 0.75 | ||
Enterprise Value to Revenue 1.66 | Enterprise Value to EBITDA 8.05 | Shares Outstanding 71500000 | Shares Floating 35699235 |
Shares Outstanding 71500000 | Shares Floating 35699235 | ||
Percent Insiders 49.99 | Percent Institutions 52.11 |
Upturn AI SWOT
DaVita HealthCare Partners Inc
Company Overview
History and Background
DaVita was founded in 1999, though its roots trace back to 1979. It evolved from a medical device company to a leading provider of kidney care services, including dialysis and related services.
Core Business Areas
- Kidney Care Services: Provides dialysis services, related lab services, and vascular access management services to patients with chronic kidney failure and end-stage renal disease.
Leadership and Structure
DaVita's leadership team includes the CEO, CFO, and various VPs overseeing operations, medical affairs, and other key functions. The organizational structure is hierarchical, with regional and divisional management overseeing dialysis clinics and related services.
Top Products and Market Share
Key Offerings
- Dialysis Services: DaVita's primary service, providing hemodialysis and peritoneal dialysis treatments. Competitors include Fresenius Medical Care, US Renal Care and independent clinics. Market share information is presented below in 'Market Share Comparison'.
- Integrated Kidney Care: Offers comprehensive kidney care management programs, including disease management, transplant support, and vascular access services. A major competitor is Fresenius Medical Care. Market share data is combined with dialysis services.
Market Dynamics
Industry Overview
The kidney care industry is characterized by increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), driven by factors such as diabetes and hypertension. The industry is heavily regulated and reliant on government reimbursement (Medicare).
Positioning
DaVita is a leading player in the dialysis services market, known for its large network of clinics, focus on quality of care, and integrated kidney care programs. It competes primarily on quality, accessibility, and service offerings.
Total Addressable Market (TAM)
The global dialysis market is estimated to be around $95 billion in 2023, expected to grow. DaVita is positioned to capture a portion of this TAM by expanding its clinic network and integrated care offerings.
Upturn SWOT Analysis
Strengths
- Large and established network of dialysis clinics
- Strong brand recognition and reputation for quality
- Integrated kidney care programs
- Established relationships with physicians and hospitals
Weaknesses
- Reliance on government reimbursement
- Exposure to regulatory changes
- High operating costs
- Sensitivity to changes in healthcare policy
Opportunities
- Expanding into new geographic markets
- Developing new and innovative dialysis technologies
- Increasing adoption of integrated kidney care programs
- Acquiring smaller dialysis providers
Threats
- Changes in government reimbursement policies
- Increased competition from other dialysis providers
- Technological advancements that could disrupt the dialysis market
- Consolidation among healthcare providers
Competitors and Market Share
Key Competitors
- FMS
- US Renal Care
Competitive Landscape
DaVita benefits from its large scale and brand recognition, but faces stiff competition from Fresenius and other players, especially as the dialysis industry consolidates.
Major Acquisitions
Reliant Medical Group's Dialysis Clinics
- Year: 2020
- Acquisition Price (USD millions): 40
- Strategic Rationale: Expanded DaVita's network of dialysis clinics in specific geographic areas.
Growth Trajectory and Initiatives
Historical Growth: DaVita has grown historically through acquisitions and organic expansion of its dialysis clinic network.
Future Projections: Future growth is expected to be driven by increasing prevalence of CKD and ESRD, as well as expansion into new markets and services.
Recent Initiatives: Recent initiatives include focusing on integrated kidney care, improving patient outcomes, and expanding its international presence.
Summary
DaVita is a leading provider of dialysis services, benefiting from a large network and brand recognition. However, the company faces challenges related to reimbursement pressures and regulatory changes. Growth opportunities lie in expanding its integrated care programs and entering new markets. Overall, DaVita holds a strong position but needs to adapt to the evolving healthcare landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports (IBISWorld, Market Research Future)
- Analyst Reports (FactSet, Bloomberg)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DaVita HealthCare Partners Inc
Exchange NYSE | Headquaters Denver, CO, United States | ||
IPO Launch date 1995-10-31 | CEO & Executive Director Mr. Javier J. Rodriguez | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76000 | Website https://www.davita.com |
Full time employees 76000 | Website https://www.davita.com | ||
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.